China Biotech Services Holdings Ltd
HKEX:8037
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
China Biotech Services Holdings Ltd
Intrinsic Value
China Biotech Services Holdings Ltd. operates as an investment company, which engages in the provision of medical laboratory testing, and health check services. [ Read More ]
The intrinsic value of one
China Biotech Services Holdings Ltd
stock under the Base Case scenario is
1.447
HKD.
Compared to the current market price of 0.365 HKD,
China Biotech Services Holdings Ltd
is
Undervalued by 75%.
China Biotech Services Holdings Ltd's market capitalization is 351.6m HKD.
China Biotech Services Holdings Ltd stock price is 0.365 HKD.
China Biotech Services Holdings Ltd stock price (0.365 HKD) is 75% less than its Intrinsic Value (1.447 HKD).
China Biotech Services Holdings Ltd stock price (0.365 HKD) is 85% less than its DCF Value (2.372 HKD). Open DCF Valuation
China Biotech Services Holdings Ltd stock price (0.365 HKD) is 30% less than its Relative Value (0.523 HKD). Open Relative Valuation
China Biotech Services Holdings Ltd.
China Biotech Services Holdings Ltd has positive Net Debt. This means that the company has more debt (91m HKD) than cash and short-term investments (72m HKD).
China Biotech Services Holdings Ltd has negative Net Income for the last twelve months.
China Biotech Services Holdings Ltd's short-term assets (261m HKD) exceed its short-term liabilties (159m HKD).
China Biotech Services Holdings Ltd has positive three-year average ROE (Return on Equity): 20%. The company is efficient at transforming stockholders' equity into net income.
China Biotech Services Holdings Ltd has negative Operating Income for the last twelve months.
China Biotech Services Holdings Ltd's Revenue has dropped by 89% over the past 12 months.
China Biotech Services Holdings Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 17% to -18%.
China Biotech Services Holdings Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 62% to -13%.
China Biotech Services Holdings Ltd's Altman Z-Score is equal to 1.99.
China Biotech Services Holdings Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -13%.
China Biotech Services Holdings Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -18%.
China Biotech Services Holdings Ltd has positive Gross Profit for the last twelve months.
China Biotech Services Holdings Ltd has positive Free Cash Flow for the last twelve months.
China Biotech Services Holdings Ltd's Revenue has been falling by 31% per year for the last 3 years.
China Biotech Services Holdings Ltd's long-term assets (662m HKD) exceed its long-term liabilties (200m HKD).
China Biotech Services Holdings Ltd's D/E (Debt to Equity) is very low and is equal to 0.2.
China Biotech Services Holdings Ltd has very high three-year average ROIC (Return on Invested Capital): 51%. The company is very efficient at using invested capital to generate operating income.
China Biotech Services Holdings Ltd doesn't generate enough operating income (-118m HKD) to safely cover interest payments on its debt (6m HKD).
Valuation Backtest
China Biotech Services Holdings Ltd
Run backtest to discover the historical profit from buying and selling
China Biotech Services Holdings Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
China Biotech Services Holdings Ltd
| Current Assets | 261.2m |
| Cash & Short-Term Investments | 72.1m |
| Receivables | 35.9m |
| Other Current Assets | 153.2m |
| Non-Current Assets | 401.2m |
| Long-Term Investments | 56.9m |
| PP&E | 124.2m |
| Intangibles | 164.8m |
| Other Non-Current Assets | 55.2m |
| Current Liabilities | 159.5m |
| Accounts Payable | 5.8m |
| Accrued Liabilities | 23.1m |
| Short-Term Debt | 84.8m |
| Other Current Liabilities | 45.7m |
| Non-Current Liabilities | 40.1m |
| Long-Term Debt | 5.7m |
| Other Non-Current Liabilities | 34.4m |
Earnings Waterfall
China Biotech Services Holdings Ltd
|
Revenue
|
212m
HKD
|
|
Cost of Revenue
|
-177.7m
HKD
|
|
Gross Profit
|
34.3m
HKD
|
|
Operating Expenses
|
-152.3m
HKD
|
|
Operating Income
|
-118m
HKD
|
|
Other Expenses
|
22.5m
HKD
|
|
Net Income
|
-95.4m
HKD
|
Free Cash Flow Analysis
China Biotech Services Holdings Ltd
| HKD | |
| Free Cash Flow | HKD |
Profitability Score
Profitability Due Diligence
China Biotech Services Holdings Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
China Biotech Services Holdings Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
China Biotech Services Holdings Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
China Biotech Services Holdings Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
China Biotech Services Holdings Ltd
Shareholder Return
Price
China Biotech Services Holdings Ltd
| Average Annual Return | -3.25% |
| Standard Deviation of Annual Returns | 9.32% |
| Max Drawdown | -89% |
| Market Capitalization | 351.6m HKD |
| Shares Outstanding | 963 231 150 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
China Biotech Services Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
China Biotech Services Holdings Ltd. operates as an investment company, which engages in the provision of medical laboratory testing, and health check services. The company employs 211 full-time employees The company went IPO on 2004-06-17. The firm is also engaged in the manufacture, research and development, sales and distribution of consumer cosmetics, health related and pharmaceutical products, health supplement wine, dental materials and equipment in the People’s Republic of China (the PRC) and Hong Kong, as well as the provision of medical laboratory testing services and health check services in Hong Kong. The firm is also involved in the property holding and money lending businesses through its subsidiaries.
Contact
IPO
Employees
Officers
The intrinsic value of one
China Biotech Services Holdings Ltd
stock under the Base Case scenario is
1.447
HKD.
Compared to the current market price of 0.365 HKD,
China Biotech Services Holdings Ltd
is
Undervalued by 75%.
You don't have any saved screeners yet
